// App-Quantinova.ai

973 : First-in-Class Autologous CD7-CAR-T Cells Exhibited Promising Clinical Efficacy for Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma

Researchers

Presenter

  • Mingzhi Zhang

Principal Investigators

  • Huimin Meng

  • Dan Chen

  • Min Wang

  • Lei Zhang

  • Ling Li

  • Xin Li

  • Xinhua Wang

  • Zhenchang Sun

  • Hui Yu

  • Zhaoming Li

  • Feifei Nan

  • Yu Chang

  • Zhiyuan Zhou

  • Jiaqin Yan

  • Jiwei Li

  • Xiaolong Wu

  • Yu Wang

  • Fengtao You

  • Yinyan Wang

  • Shufen Xiang

  • Yu-Sheng Chen

  • Guifang Pan

  • Hanying Xu

  • Bozhen Zhang

  • Lin Yang

Medical Centers

  • Department of Interventional Therapy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

  • Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China

  • PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou, China

  • PersonGen-Anke Cellular Therapeutics Co., Ltd., Hefei, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • T-cell acute lymphoblastic leukemia

  • Acute lymphoblastic leukemia

  • Lymphomas

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

Outcome

  • N/A

Study Design

  • First-In-Human

Phase

  • I

Study Id's

  • NCT04004637

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved